Study Group 1 for Retinitis Pigmentosa

CHNO XV-XX Paris - CIC 1423, Paris, France
Ophthalmic examinations +1 moreN/AWaitlist AvailableLed by Saddek Mohand-Saïd, MD, PhDResearch Sponsored by SparingVision

Study Summary

This trial is looking at the effects of different mutations that cause Retinitis Pigmentosa, a degenerative disease of the retina.

Eligible Conditions
  • Retinitis Pigmentosa


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Fundus Autofluorescence (FAF)
Spectral Domain Optical Coherence tomography (SD-OCT)
Secondary outcome measures
Color vision
Dark adaptometry (DA)
Full-field stimulus threshold (FST)
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Study Group 2Experimental Treatment2 Interventions
Four years follow-up of patients with ophthalmic examination and mobility testing.
Group II: Study Group 1Experimental Treatment1 Intervention
Four years follow up of patients with ophthalmic examination.

Find a site

Who is running the clinical trial?

SparingVisionLead Sponsor
2 Previous Clinical Trials
146 Total Patients Enrolled
2 Trials studying Retinitis Pigmentosa
146 Patients Enrolled for Retinitis Pigmentosa
Saddek Mohand-Saïd, MD, PhDPrincipal Investigator
CHNO XV-XX Paris - CIC 1423
Isabelle Audo, MD, PhDPrincipal Investigator
CHNO XV-XX Paris - CIC 1423

Media Library

Study Group 1 Clinical Trial Eligibility Overview. Trial Name: NCT04285398 — N/A
Retinitis Pigmentosa Research Study Groups: Study Group 1, Study Group 2
Retinitis Pigmentosa Clinical Trial 2023: Study Group 1 Highlights & Side Effects. Trial Name: NCT04285398 — N/A
Study Group 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT04285398 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What ultimate goal is this medical research aiming to attain?

"This clinical study, lasting approximately 12 months, will measure the progression of disease over time through Fundus Autofluorescence (FAF), Dark Adaptometry (DA) refraction and visual acuity using ETDRS or Snellen scales as well as Full-field Stimulus Thresholds (FST)."

Answered by AI

Is this experiment still recruiting participants?

"According to, this particular medical study is not currently recruiting participants; the trial was initially posted on February 12th 2020 and last updated on April 19th 2022. Despite this fact, there are 51 other research initiatives that are actively enrolling patients at present."

Answered by AI
~35 spots leftby Jun 2026